(Q44497625)

3 December 2017

0 references

A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure (English)

1 reference

3 December 2017

main subject

chronic heart failure

1 reference

Bo Jin

1

1 reference

3 December 2017

Xinping Luo

2

1 reference

3 December 2017

Haihong Lin

3

1 reference

3 December 2017

Jian Li

4

1 reference

3 December 2017

Haiming Shi

5

1 reference

3 December 2017

language of work or name

1 reference

22 December 2009

1 reference

European Journal of Heart Failure

3 December 2017

published in

1 reference

3 December 2017

volume

12

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

249-253

1 reference

Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Systematic review: cardiac resynchronization in patients with symptomatic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Symptomatic relief: left ventricular assist devices versus resynchronization therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Stem-cell transplantation in myocardial infarction: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Anemia and chronic heart failure implications and treatment options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Anemia and its relationship to clinical outcome in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

What factors are associated with high plasma B-type natriuretic peptide levels in a general Japanese population?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Erythropoietin treatment in patients with chronic heart failure: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP182

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFP182

1 reference

3 December 2017

1 reference